These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 29702999)

  • 21. Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity.
    Daneshpazhooh M; Chams-Davatchi C; Khamesipour A; Mansoori P; Taheri A; Firooz A; Mortazavi H; Esmaili N; Dowlati Y
    J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1319-24. PubMed ID: 17958835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab in pemphigus foliaceous with autoantibodies against both Desmoglein 1 and Desmoglein 3.
    Carvalho R; Maio P; Cunha D; Freitas I; Afonso A; Cardoso J
    Eur J Dermatol; 2011; 21(3):415-6. PubMed ID: 21527367
    [No Abstract]   [Full Text] [Related]  

  • 23. [Intravenous immunoglobulin therapy: ELISA measurement of antidesmogleins 1 and 3 in three patients with pemphigus vulgaris].
    Suárez-Fernández R; Longo I; Avilés JA; Bueno C; Rodríguez-Mahou M; Lázaro P
    Rev Clin Esp; 2006 Nov; 206(10):499-503. PubMed ID: 17129517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prolonged complete clinical remission in patients with severe pemphigus vulgaris after cycles of intravenous cyclophosphamide].
    España Alonso A; Panizo C; Fernández S; Marquina M; Pretel M; Aguado L; Sánchez-Ibarrola A
    Actas Dermosifiliogr; 2009 Mar; 100(2):113-20. PubMed ID: 19445875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum and salivary desmoglein 1 and 3 enzyme-linked immunosorbent assay in pemphigus vulgaris: correlation with phenotype and severity.
    Hallaji Z; Mortazavi H; Lajevardi V; Tamizifar B; AmirZargar A; Daneshpazhooh M; Chams-Davatchi C
    J Eur Acad Dermatol Venereol; 2010 Mar; 24(3):275-80. PubMed ID: 19709345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-Term Intravenous Infusion of Cyclophosphamide in the Treatment of Refractory Pemphigus Vulgaris: A Retrospective Study.
    Zhang W; Wei S; Peng X; Xie S; Zhang Z; Zeng K; Lai K
    Dermatology; 2021; 237(2):185-190. PubMed ID: 32814321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid transition from pemphigus vulgaris to pemphigus foliaceus.
    Ito T; Moriuchi R; Kikuchi K; Shimizu S
    J Eur Acad Dermatol Venereol; 2016 Mar; 30(3):455-7. PubMed ID: 25376758
    [No Abstract]   [Full Text] [Related]  

  • 28. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption.
    Eming R; Rech J; Barth S; Kalden JR; Schuler G; Harrer T; Hertl M
    Dermatology; 2006; 212(2):177-87. PubMed ID: 16484825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IgG/IgA pemphigus with IgG and IgA antidesmoglein 3 antibodies and IgA antidesmoglein 1 antibodies detected by enzyme-linked immunosorbent assay: a case report and review of the literature.
    Zaraa I; Kerkeni N; Sellami M; Chelly I; Zitouna M; Makni S; Mokni M; Ben Osman A
    Int J Dermatol; 2010 Mar; 49(3):298-302. PubMed ID: 20465668
    [No Abstract]   [Full Text] [Related]  

  • 30. Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients.
    Schmidt E; Dähnrich C; Rosemann A; Probst C; Komorowski L; Saschenbrecker S; Schlumberger W; Stöcker W; Hashimoto T; Bröcker EB; Recke A; Rose C; Zillikens D
    Exp Dermatol; 2010 May; 19(5):458-63. PubMed ID: 20163452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Herpetiform pemphigus without anti-desmoglein 1/3 autoantibodies.
    Nakashima H; Fujimoto M; Watanabe R; Ishiura N; Yamamoto AI; Hashimoto T; Tamaki K
    J Dermatol; 2010 Mar; 37(3):264-8. PubMed ID: 20507392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cutaneous pemphigus vulgaris with absence of desmoglein 1 autoantibodies. An example of the extended desmoglein compensation theory.
    Carew B; Wagner G
    Australas J Dermatol; 2014 Nov; 55(4):292-5. PubMed ID: 25399788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Juvenile pemphigus vulgaris].
    Janisson-Dargaud D; Reguiaï Z; Perceau G; Eschard C; Bernard P
    Ann Dermatol Venereol; 2008 Dec; 135(12):843-7. PubMed ID: 19084695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of antimuscarinic acetylcholine receptor antibody titers and antidesmoglein antibody titers with the severity of disease in patients with pemphigus.
    Lakshmi MJD; Jaisankar TJ; Rajappa M; Thappa DM; Chandrashekar L; Divyapriya D; Munisamy M; Revathy G
    J Am Acad Dermatol; 2017 May; 76(5):895-902. PubMed ID: 28089115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of chemiluminescent enzyme immunoassay in detection of autoantibodies in pemphigus and pemphigoid.
    Fujio Y; Kojima K; Hashiguchi M; Wakui M; Murata M; Amagai M; Yamagami J
    J Dermatol Sci; 2017 Mar; 85(3):208-215. PubMed ID: 28012821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of pemphigus desmoglein 1 and desmoglein 3 autoantibodies and pemphigoid BP180 autoantibodies in saliva and comparison with serum values.
    Andreadis D; Lorenzini G; Drakoulakos D; Belazi M; Mihailidou E; Velkos G; Mourellou-Tsatsou O; Antoniades D
    Eur J Oral Sci; 2006 Oct; 114(5):374-80. PubMed ID: 17026501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coexistence of pemphigus vulgaris and bullous pemphigoid in the upper aerodigestive tract.
    Tabuchi K; Nomura M; Murashita H; Fujisawa Y; Tsuji S; Okubo H; Hara A
    Auris Nasus Larynx; 2006 Jun; 33(2):231-3. PubMed ID: 16168587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of the Prevalence and Risk Factors Associated With Glucocorticoid-Induced Diabetes Mellitus in Pemphigus Vulgaris Patients.
    Darjani A; Nickhah N; Hedayati Emami MH; Alizadeh N; Rafiei R; Eftekhari H; Gharaei Nejad K
    Acta Med Iran; 2017 Jun; 55(6):375-380. PubMed ID: 28843238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recalcitrant facial pemphigus vulgaris: correlation of skin lesions with the ratio of antidesmoglein antibodies 1 and 3.
    Fujii M; Honma M; Iinuma S; Kaneta K; Komatsu S; Sato K; Takahashi H; Ishida-Yamamoto A; Iizuka H
    Clin Exp Dermatol; 2011 Apr; 36(3):284-7. PubMed ID: 21418270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neonatal pemphigus vulgaris.
    Gushi M; Yamamoto Y; Mine Y; Awazawa R; Nonaka K; Taira K; Asato Y; Hagiwara K; Uezato H
    J Dermatol; 2008 Aug; 35(8):529-35. PubMed ID: 18789074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.